Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Crunchometer: open-source feeding analysis
An open-source acoustic device for mice detects semaglutide appetite suppression and maps meal-tracking neurons in the lateral hypothalamus.
GLP-1 vs oral agents: insulin stop in T2D
A 2026 Annals study found GLP-1 agonists did not raise insulin discontinuation rates above SGLT-2 or DPP-4 inhibitors in 8,869 veterans with type 2 diabetes.
GLP-1 cancer risk vs bariatric surgery
A July 2026 study found GLP-1 receptor agonists were tied to lower colorectal and pancreatic cancer rates than bariatric surgery, not higher.
CRAVE study: GLP-1, food cravings, and diet
The CRAVE study tracked 28 adults on GLP-1 agonists for 24 weeks. Weight fell, diet quality did not improve, and micronutrient intake dropped.
How muscarine weakens heart contractions
Muscarine reduces cardiac contractile force in human atrial tissue only when cAMP is already elevated, including by GLP-1 agonists like semaglutide.
The obesity drug pipeline in 2026
A 2026 JCEM review maps next-generation obesity drugs, from approved dual agonists to triple agonists like retatrutide still in Phase 3.
Semaglutide for MASH: the corrected review
Liver International published an erratum in August 2026 to the Petta et al. semaglutide MASH review. Here is what the original said and what a correction means.
Semaglutide optic neuropathy: correction
JCEM Case Reports issued a formal correction in July 2026 to a May 2026 case report on optic nerve injury after semaglutide escalation.
Tirzepatide: PERCEPTIONS survey findings
The PERCEPTIONS survey (n=518, US) found health improvement was the top reason patients started tirzepatide; cost and insurance were the main barriers.
Mounjaro on X: who shapes the conversation
A 2026 study of 5,566 Mounjaro tweets found that the top influencers on X are patients and public figures, not clinicians.
Semaglutide alters NAc oscillations in mice
Molecular Brain (July 2026) finds semaglutide changes nucleus accumbens oscillations and reward behaviour in healthy mice, not just in metabolic disease models.
TAAR1: the metabolic target after GLP-1
A 2026 pharmacology review argues TAAR1 can replicate GLP-1 agonist effects through a distinct receptor, with additional action on brain reward circuits.